Incobotulinum Toxin-A Improves Post-Surgical and Post-Radiation Pain in Cancer Patients

Toxins (Basel). 2016 Jan 13;8(1):22. doi: 10.3390/toxins8010022.


Cancer patients who undergo surgery or radiation can develop persistent focal pain at the site of radiation or surgery. Twelve patients who had surgery or radiation for local cancer and failed at least two analgesic medications for pain control were prospectively enrolled in a research protocol. Patients were injected up to 100 units of incobotulinum toxin A (IncoA) intramuscularly or subcutaneously depending on the type and location of pain (muscle cramp or neuropathic pain). Two patients passed away, one dropped out due to a skin reaction and another patient could not return for the follow up due to his poor general condition. All remaining 8 subjects (Age 31-70, 4 female) demonstrated significant improvement of Visual Analog Scale (VAS) (3 to 9 degrees, average 3.9 degrees) and reported significant satisfaction in Patients' Global Impression of Change scale (PGIC) (7 out of 8 reported the pain as much improved). Three of the 8 patients reported significant improvement of quality of life.

Keywords: Patients’ Global Impression of Change; cancer pain; incobotulinum toxin A; onabotulinum toxin A; radiation; surgery; visual analog scale.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Analgesics / adverse effects
  • Analgesics / therapeutic use*
  • Botulinum Toxins, Type A / adverse effects
  • Botulinum Toxins, Type A / therapeutic use*
  • Chronic Pain / drug therapy
  • Female
  • Humans
  • Injections, Intramuscular
  • Injections, Subcutaneous
  • Male
  • Middle Aged
  • Neoplasms / drug therapy
  • Neuralgia / drug therapy*
  • Pain Measurement
  • Pain, Postoperative / drug therapy*
  • Quality of Life
  • Treatment Outcome


  • Analgesics
  • Botulinum Toxins, Type A
  • incobotulinumtoxinA